Company Focus
Amgen
Latest Amgen News
Pharmaceutical
French pharma Sanofi reported mixed Phase II data for lunsekimig, with the dual-target nanobody hitting key endpoints in asthma and chronic rhinosinusitis with nasal polyps, but missing its primary goal in atopic dermatitis. 7 April 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing Immuno-STAT biologics that selectively modulate T cell activity for cancer and autoimmune diseases.
Latest News & Features of interest to Amgen
Biotechnology
German biotech BioNTech today announced positive results from the primary analysis of a Phase II cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing, advanced endometrial cancer whose disease progressed on or after first-line chemotherapy with or without prior checkpoint inhibitor treatment. 11 April 2026
Pharmaceutical
The UK’S Medicines and Healthcare products Regulatory Agency (MHRA) has approved Swedish Orphan Biovitrum Tryngolza (olezarsen) to help treat adults with familial chylomicronemia syndrome (FCS). 11 April 2026
Biotechnology
Japanese drugmaker Daiichi Sankyo is deepening its push into AI-driven oncology, partnering with USA-based Imagene AI to advance biomarker discovery and response prediction across its cancer pipeline. 10 April 2026
Pharmaceutical
Tempus AI , a technology company leading the adoption of AI to advance precision medicine, has announced an expanded, multi-year collaboration with Gilead Sciences aimed at building and advancing Gilead’s oncology pipeline. 10 April 2026
Biotechnology
Swedish immuno-oncology firm Alligator Bioscience saw its shares jump 28.7% to 0.20 kronor this morning, after it provided a brief update regarding its mitazalimab. 10 April 2026
Biotechnology
US clinical-stage biotech C4 Therapeutics (C4T) announced that it has entered into a new collaboration agreement with Roche to advance research in the emerging degrader-antibody conjugate (DAC) modality. 10 April 2026
Pharmaceutical
US pharma major AbbVie has filed a lawsuit seeking to narrow the definition of a “340B patient,” opening a new legal front in a long-running dispute over the US drug discount program. 9 April 2026
Pharmaceutical
US biotech Sidewinder Therapeutics has secured $137 million in an oversubscribed series B financing to advance its bispecific antibody-drug conjugate (ADC) pipeline for cancer. 9 April 2026
Pharmaceutical
US specialty pharma company Cosette Pharmaceuticals announced the closing of a definitive agreement to acquire the US sales and distribution rights for a portfolio of seven branded products from Assertio Holdings. 9 April 2026
Biotechnology
Late last year, Julie Dehaene-Puype stepped into the role of Regional President at Kyowa Kirin International (KKI), a specialty pharma developing innovative treatments for rare and genetic diseases, including bone and mineral disorders, rare blood cancers and other inherited genetic conditions. 8 April 2026
Latest In Brief for Amgen
Biotechnology
US Biotech company Regenxbio and the University of Pennsylvania on Friday convinced a US appeals court to revive their patent lawsuit against Sarepta Therapeutics over Sarepta's Duchenne muscular dystrophy (DMD) treatment, according to a Reuters report. 23 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze